Phenothiazine Derivatives Modulate ABCC1 Transporter for Amyloid Reduction
Solution Overview
Problem
Current methods fail to effectively address the accumulation of β-amyloid peptides in the brain, which is a hallmark of neurodegenerative diseases like Alzheimer's and Parkinson's, and there is a lack of attention to the role of ABC transporters in their removal.
Innovation Solution
The use of 2-(R2-thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazines to modulate the activity of the ABCC1 transporter, which is crucial for the transport of β-amyloid peptides across the blood-brain barrier, and the development of a diagnostic method involving the analysis of substance concentrations in bodily fluids to assess transporter activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If ABC transporters are targeted to remove β-amyloid peptides, then cerebral β-amyloid load is reduced, but diagnostic methods for detecting transporter activity are lacking
Solution Approach 1:
The patent uses phenothiazine derivatives as intermediary substances that are transported by ABCC1 transporters. These compounds serve as mediators to indirectly measure transporter activity - by administering a known amount of the intermediary substance and measuring its concentration in bodily fluids, the functional status of the ABCC1 transporter can be assessed without directly measuring the transporter itself.
Solution Approach 2:
The patent replaces direct mechanical/biological measurement of transporter activity with a chemical substitution approach. Instead of directly measuring the ABCC1 transporter's function, the method uses chemical compounds (phenothiazine derivatives) as proxies, measuring their transport and metabolism to infer transporter activity. This substitutes a complex biological measurement with a chemical analysis of substance concentrations.
2Reliability
If ABCC1 transporter activity is increased to clear β-amyloid, then disease progression is slowed, but substances affecting ABCC1 must be carefully selected to avoid side effects
Solution Approach 1:
The patent modifies the chemical structure of phenothiazine derivatives by changing parameters such as substituting sulfur for oxygen in the phenothiazine ring, adding specific side chains (piperazinylpropyl groups), and adjusting molecular weight and lipophilicity. These parameter changes optimize the compounds' affinity for ABCC1 transporters while improving their safety profile and reducing unwanted side effects compared to conventional phenothiazines.
Data Source
Figure 1a
Figure 1b
Figure 1c
AI summary
Use of substituted 10-(3-piperazin-1-yl-propyl)-10H-phenothiazine-2-thiol compounds (I) for treating neurodegenerative diseases, is claimed. Use of substituted 10-(3-piperazin-1-yl-propyl)-10H-phenothiazine-2-thiol compounds of formula (I) for treating neurodegenerative diseases, is claimed. R1, R2 : 1-6C-alkyl (optionally substituted by alkyl (optionally substituted by at least one further halo atom), aryl, acyl, acetyl, amino, nitro, sulfonyl, hydroxyl, alkoxy, aryloxy, arylthio, alkylthio or halo); R3 : H, alkyl (optionally substituted by at least one further halo atom), aryl, acyl, acetyl, amino, nitro, sulfonyl, hydroxyl, alkoxy, aryloxy, arylthio, alkylthio, halo, NR4R5- or OR6; R4-R6 : H or 1-3C-alkyl; R7 : H, alkyl (optionally substituted by at least one further halo atom), aryl, acyl, acetyl, amino, nitro, sulfonyl, hydroxyl, alkoxy, aryloxy, arylthio, alkylthio, halo, NR8R9 or OR10; and R8-R10 : H or 1-3C-alkyl. [Image] ACTIVITY : Neuroprotective; Nootropic; Anticonvulsant; Antiparkinsonian; Cerebroprotective; Hypnotic; Antiinflammatory. MECHANISM OF ACTION : None given.